Skip to main content
TipRanks
Go Ultimate75% OFF

Endonovo Therapeutics (ENDV) Stock Statistics & Valuation Metrics

24 Followers

Total Valuation

Endonovo Therapeutics has a market cap or net worth of $180.76K. The enterprise value is $6.93T.

Market Cap
$180.76K
Enterprise Value
$6.93T

Share Statistics

Endonovo Therapeutics has 1,807,556,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,807,556,300
Owned by Insiders
―
Owned by Institutions
<0.01%

Financial Efficiency

Endonovo Therapeutics’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.32%.

Return on Equity (ROE)
0.08
Return on Assets (ROA)
-112.75
Return on Invested Capital (ROIC)
4.32%
Return on Capital Employed (ROCE)
0.03
Revenue Per Employee
0
Profits Per Employee
-2.18M
Employee Count
1
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Endonovo Therapeutics is -0.08. Endonovo Therapeutics’s PEG ratio is -0.00.

PE Ratio
-0.08
PS Ratio
0.00
PB Ratio
-0.01
Price to FCF
-0.19
Price to Operating Cash Flow
-1.06
PEG Ratio
-0.00

Income Statement

In the last 12 months, Endonovo Therapeutics had revenue of 0 and earned -2.18M in profits. Earnings per share was -0.00.

Revenue
0
Gross Profit
0
Operating Income
-945.77K
Pretax Income
-2.18M
Net Income
-2.18M
EBITDA
-945.77K
Earnings Per Share (EPS)
-0.00

Cash Flow

In the last 12 months, operating cash flow was -169.78K and capital expenditures 5, giving a free cash flow of -169.77K billion.

Operating Cash Flow
-169.78K
Free Cash Flow
-169.77K
Free Cash Flow per Share
-0.00

Dividends & Yields

Endonovo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-532.61%
Earnings Yield
-1278.26%

Stock Price Statistics

Beta
280.11
52-Week Price Change
-97.94%
50-Day Moving Average
―
200-Day Moving Average
―
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Endonovo Therapeutics upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date
Nov 18, 2024
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

Endonovo Therapeutics as a current ratio of 0.00, with Debt / Equity ratio of -23.95%

Current Ratio
0.00
Quick Ratio
0.00
Debt to Market Cap
62.97
Net Debt to EBITDA
-7.31
Interest Coverage Ratio
-0.76

Taxes

In the past 12 months, Endonovo Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Endonovo Therapeutics EV to EBITDA ratio is -6.62, with an EV/FCF ratio of -41.86.

EV to Sales
0.00
EV to EBITDA
-6.62
EV to Free Cash Flow
-41.86
EV to Operating Cash Flow
-41.86

Balance Sheet

Endonovo Therapeutics has $13.68K in cash and marketable securities with $7.09M in debt, giving a net cash position of -$7.08M billion.

Cash & Marketable Securities
$13.68K
Total Debt
$7.09M
Net Cash
-$7.08M
Net Cash Per Share
$0.00
Tangible Book Value Per Share
-$0.02

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Endonovo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
48.00%

Scores

Smart Score
―
AI Score
35